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Summary 
Background The genetic basis of lacunar stroke is poorly understood, with a single locus on 16q24 identified to date. 
We sought to identify novel associations and provide mechanistic insights into the disease.
Methods We did a pooled analysis of data from newly recruited patients with an MRI-confirmed diagnosis of lacunar 
stroke and existing genome-wide association studies (GWAS). Patients were recruited from hospitals in the UK as part of 
the UK DNA Lacunar Stroke studies 1 and 2 and from collaborators within the International Stroke Genetics Consortium. 
Cases and controls were stratified by ancestry and two meta-analyses were done: a European ancestry analysis, and a 
transethnic analysis that included all ancestry groups. We also did a multi-trait analysis of GWAS, in a joint analysis with 
a study of cerebral white matter hyperintensities (an aetiologically related radiological trait), to find additional genetic 
associations. We did a transcriptome-wide association study (TWAS) to detect genes for which expression is associated 
with lacunar stroke; identified significantly enriched pathways using multi-marker analysis of genomic annotation; and 
evaluated cardiovascular risk factors causally associated with the disease using mendelian randomisation.
Findings Our meta-analysis comprised studies from Europe, the USA, and Australia, including 7338 cases and 
254 798 con trols, of which 2987 cases (matched with 29 540 controls) were confirmed using MRI. Five loci 
(ICA1L-WDR12-CARF-NBEAL1, ULK4, SPI1-SLC39A13-PSMC3-RAPSN, ZCCHC14, ZBTB14-EPB41L3) were found 
to be associa ted with lacunar stroke in the European or transethnic meta-analyses. A further seven loci 
(SLC25A44-PMF1-BGLAP, LOX-ZNF474-LOC100505841, FOXF2-FOXQ1, VTA1-GPR126, SH3PXD2A, HTRA1-ARMS2, 
COL4A2) were found to be associated in the multi-trait analysis with cerebral white matter hyperintensities (n=42 310). 
Two of the identified loci contain genes (COL4A2 and HTRA1) that are involved in monogenic lacunar stroke. The 
TWAS identified associations between the expression of six genes (SCL25A44, ULK4, CARF, FAM117B, ICA1L, 
NBEAL1) and lacunar stroke. Pathway analyses implicated disruption of the extracellular matrix, phosphatidylinositol 
5 phosphate binding, and roundabout binding (false discovery rate <0·05). Mendelian randomisation analyses identified 
positive associations of elevated blood pressure, history of smoking, and type 2 diabetes with lacunar stroke.
Interpretation Lacunar stroke has a substantial heritable component, with 12 loci now identified that could represent 
future treatment targets. These loci provide insights into lacunar stroke pathogenesis, highlighting disruption of the 
vascular extracellular matrix (COL4A2, LOX, SH3PXD2A, GPR126, HTRA1), pericyte differentiation (FOXF2, 
GPR126), TGF-β signalling (HTRA1), and myelination (ULK4, GPR126) in disease risk.
Funding British Heart Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
Lacunar strokes are small subcortical infarcts that arise 
from ischaemia in the territory of the deep perforating 
arteries of the brain.1,2 They account for up to a quarter of 
all ischaemic strokes and are usually due to cerebral small 
vessel disease, which is also the most common pathol­
ogy underlying intracerebral haemorrhage and vascular 
cognitive impairment. Radiologically, small vessel disease 
is also characterised by the presence of cerebral white 
matter hyperintensities, enlarged perivascular spaces, 
microbleeds, and brain atrophy.3 Few therapeutic inter­
ventions have been shown to reduce small vessel disease. 
One obstacle to developing new therapeutic approaches 
has been a lack of understanding of the underlying 
pathophysiology. One method that has been successfully 
used to discover pathophysiological processes and uncover 
potential treatment targets in other complex diseases is the 
use of genetic data derived from genome­wide associ ation 
studies (GWAS). Recent GWAS have identified 35 loci 
associated with risk of ischaemic stroke and its major 
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subtypes;4–6 but although many loci have been identi fied 
with the other major stroke subtypes (cardioembolic and 
large artery stroke), only one locus (16q24) has been 
robustly shown to be associated with lacunar stroke to 
date.6 This is surprising because lacunar stroke is the 
stroke subtype most likely to be caused by monogenic 
disease,7 and sporadic lacunar stroke has been strongly 
associated with a family history of stroke.8 Additionally, 
studies of other MRI markers of cerebral small vessel 
disease have shown a substantial genetic component; a 
recent GWAS identified 31 loci across three phenotypes.9
Methods 
Study design and phenotype definitions 
We did a GWAS of lacunar stroke to identify novel 
associations and provide mechanistic insights into 
lacunar stroke. We recruited cases of lacunar stroke 
from hospitals across the UK as part of the UK DNA 
Lacunar Stroke studies 1 and 2,10 and from collaborators 
within the International Stroke Genetics Consortium; 
and re­analysed data from previous studies.11–14 Because 
MRI confirmation of lacunar stroke is more reliable 
than standard phenotyping,15,16 we focused on recruiting 
MRI­confirmed cases. First, we did a GWAS of these 
data to identify novel genetic loci associated with lacunar 
stroke. Second, we used a multi­trait approach to detect 
additional genetic variation associated with lacunar 
stroke in a joint analysis with cerebral white matter 
hyperintensities from a large­scale GWAS.9 Third, we 
did a transcriptome­wide association study (TWAS) to 
identify transcribed genes for which expression is 
associated with lacunar stroke, and used mendelian 
randomisation to assess common cardio vascular risk 
factors that contribute to the disease. We did separate 
analyses in MRI­confirmed and standard phenotyping 
groups to assess whether MRI confirmation improves 
power to detect genetic associations.
For the GWAS, lacunar stroke cases were recruited 
from a combina tion of acute stroke admissions and 
outpatient ser vices from Europe, the USA, South America, 
and Australia. Study inclusion criteria are detailed 
in the appendix (pp 99–114). Cases and controls were 
stratified by ancestry (European, south Asian, African, 
Hispanic) and analysed separately. We did two meta­
analyses: a European ancestry analysis, and a transethnic 
analysis that included all ancestry groups. For each 
contributing study, approval for inclusion in this analysis 
complied with local ethical standards and with local 
institutional review board or ethics committee over sight. 
All participants provided written informed consent for 
genetic studies.
Lacunar stroke samples were divided into two strata: 
the MRI­confirmed group and the standard phenotyping 
group. In the MRI­confirmed group, lacunar stroke was 
defined as a clinical lacunar syndrome17 with an anatom­
ically compatible lesion on MRI (subcortical infarct, 
≤15 mm in diameter), either as a region of high intensity 
on diffusion­weighted imaging for acute infarcts or as 
a region of low intensity on fluid­attenuated inversion 
recovery or T1 imaging for non­acute infarcts,3 and the 
absence of causes of stroke other than small vessel disease. 
MRIs were centrally reviewed according to a standard 
proforma to confirm the diagnosis of lacunar stroke and 
identify any exclusion criteria. All patients underwent 
comprehensive stroke investigation, including brain MRI, 
imaging of the carotid arteries, and electro cardiogram. 
Echocardiography was done if appropriate. Exclusion 
criteria were stenosis of more than 50% in the extracranial 
or intracranial cerebral vessels, or previous carotid end­
arterectomy; cardioembolic source of stroke, defined 
according to criteria from the TOAST trial11 as high or 
moderate probability; cortical infarct on MRI; subcortical 
infarct of more than 15 mm in diameter, because these 
can be caused by embolic mechanisms (striato capsular 
Research in context
Evidence before this study
Using the terms “stroke”, “small vessel stroke”, “lacunar stroke”, 
“small vessel disease”, “white matter hyperintensities”, 
“genetics”, and “GWAS”, we searched PubMed and GWAS 
Catalog for relevant reports published between Jan 1, 2010, 
and Jan 1, 2020. We considered only peer-reviewed reports in 
English. Previously, a single locus on chromosome 16q24 has 
been robustly associated specifically with lacunar stroke; 
by contrast, more than 30 loci have been associated with broad 
stroke phenotypes.
Added value of this study
The present findings substantially expand the number of 
genetic associations with lacunar stroke, with five loci now 
associated directly and a further seven associated with lacunar 
stroke jointly with white matter hyperintensities. These loci 
highlight several key mechanisms in lacunar stroke 
pathogenesis, including extracellular matrix dysfunction, 
myelination, and pericyte differentiation. The current findings 
also show that individuals with increased genetic predisposition 
to elevated blood pressure, smoking, and type 2 diabetes are at 
increased risk of lacunar stroke, suggesting a causal role for 
these factors.
Implications of all the available evidence
No treatments for prevention of lacunar stroke are available, 
aside from management of vascular risk factors, such as blood 
pressure. This is due in part to poor understanding of the 
mechanisms underlying the disease. Our findings highlight 
novel mechanisms underlying lacunar stroke pathogenesis, and 
therefore point to pathways that have potential to be targeted 
by therapeutics. Improved treatment of elevated blood pressure 
and type 2 diabetes, as well as prevention of smoking in the 
population, is likely to reduce the burden of lacunar stroke.
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infarcts); and any other specific cause of stroke (eg, 
lupus anticoagulant, cerebral vasculitis, dissec tion, and 
monogenic cause of stroke).
In the standard phenotyping group, lacunar stroke was 
defined according to the TOAST criteria,11 based on a 
clinical lacunar syndrome and the absence of other causes 
of stroke, or non­lacunar infarction on CT.
Genotyping and imputation 
Genotyping arrays, quality control filters, and imputation 
reference panels are listed in the appendix (pp 7–8). All 
studies inferred the genetic ancestry of samples by 
comparison with reference populations using principal 
components analysis. European samples in this study are 
defined as those that segregated with European ancestry 
reference samples. The majority of studies were imputed 
to the Haplotype Reference Consortium build. If this 
was not possible due to logistical or ethical reasons, 
imputation to 1000 Genomes Phase 3 (all ancestry groups) 
panels was used.14,18
Statistical analysis 
All studies used logistic regression to assess the association 
of single nucleotide polymorphism (SNP) allele dosages 
with lacunar stroke, including ancestry informative princi­
pal components as covariates as appropriate. All studies 
included cases with geographically matched controls, as 
confirmed by principal components analysis. Some studies 
had a combination of cases based on TOAST diagnosis 
of lacunar stroke, which were re­analysed for MRI 
confirmation of lacunar stroke, and cases based on TOAST 
diagnosis of lacunar stroke only, for which MRI was either 
not acquired or was inaccessible. In these circumstances, 
we analysed the MRI­confirmed and TOAST only (stan­
dard phenotyping) groups separately and divided the study 
controls between the two groups to avoid any sample 
overlap. Any cases with subsequent MRI confirmation of 
lacunar stroke were omitted from the TOAST only group; 
all individuals were analysed only once.
Meta­analysis was done based on a fixed­effects inverse­
variance weighted procedure using the METAL tool.19 
Meta­analysis was done in the MRI­confirmed and standard 
phenotyping groups separately, and in all studies com­
bined. We used the principles described by Winkler and 
colleagues20 to scrutinise datasets used in the meta­analysis. 
For each study, we filtered out SNPs with imputa tion 
INFO scores of less than 0·7 or minor allele frequency 
(MAF) of less than 0·01. Additionally, we removed low 
frequency or poorly imputed SNPs in smal ler studies by 
removing variants for which INFO × MAF × number of 
cases equalled less than 2.5 Genomic control correction 
based on genomic inflation factor λ was used for each study 
to adjust for any residual inflation.21 Linkage disequilibrium 
(LD) score intercept values were used to assess whether 
population structure had been sufficiently resolved at 
the meta­analysis level.22 After meta­analysis, we excluded 
SNPs that were not present in at least 50% of cases.
We defined significant loci as those containing SNPs 
with a p value of less than 5 × 10–⁸ and in linkage equilibrium 
(r²>0·1) with other lead SNPs. If multiple loci met these 
criteria within 1 Mb we used conditional and joint multiple 
SNP analysis (GCTA­cojo) to evaluate whether these SNPs 
remained genome­wide significant in a joint modelling 
scenario.23 We used Nagelkerke R² values to calculate 
the proportion of variance explained by genome­wide 
significant SNPs using the NagelkerkeR2 function in the 
R fmsb library.24 To obtain an estimate of R², we subtracted 
the R² estimate for the model that included only principal 
components from the model that also contained the 
genome­wide significant SNPs. We used a genome­based 
restricted maximum likelihood (GREML) approach, imple­
mented in GCTA software,25,26 and LD score regression,22 to 
estimate the heritability of lacunar stroke (MRI­confirmed 
and non­confirmed).
We did multi­trait analysis of GWAS (MTAG),27 
performing a joint analysis with a large study of cerebral 
white matter hyperintensities on MRI (n=42 310),9 which 
shares a common cause with lacunar stroke through 
cerebral small vessel disease, to uncover additional genetic 
variation associated with lacunar stroke. We considered 
associations significant if they had a p value of less than 
5 × 10–⁸ in MTAG, had a p value of less than 0·05 for 
association with white matter hyperintensities and lacunar 
stroke in univariate analysis, and showed greater signi­
ficance in MTAG than in univariate analyses for white 
matter hyperintensities or lacunar stroke. To confirm our 
associations, we used an alternative approach, Bayesian 
multivariate analysis of summary statistics (using 
R package BMASS).28
We used the TWAS approach to identify genes for which 
genetically altered expression was associated with lacunar 
stroke. Analyses were done using FUSION,29 from gene 
expression models derived from the Genotype­Tissue 
Expression (GTEx) portal V7,30 CommonMind Consortium 
Figure 1: Analysis pipeline
GWAS=genome-wide association study.
GWAS in TOAST-phenotyped 
lacunar stroke group 
(4351 cases, 225 258 controls)
GWAS in MRI-confirmed 
lacunar stroke group
(2987 cases, 29 540 controls)
Meta-analysis of MRI-confirmed 
and TOAST groups 
(European analysis: 6030 cases, 
248 929 controls; transethnic 
analysis: 7338 cases, 
254 798 controls) 
Multi-trait analysis of lacunar 
stroke and white matter 
hyperintensities
GWAS of white matter 
hyperintensity volumes 
(n=42 310)
Mendelian randomisation to 
identify causal cardiovascular 
risk factors
Transcriptome-wide association 
study and colocalisation to 
identify implicated genes
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(CMC),31 and Young Finns Study (YFS) datasets.32 The 
CMC gene expression tissues (labelled as CMC brain) 
were collected from the dorso lateral prefrontal cortex of 
individuals with schizophrenia or controls (TWAS n=452). 
In the YFS study (labelled as YFS whole blood), peripheral 
blood gene expression was analysed (TWAS n=1264). 
Among the available GTEx tissues, we focused our TWAS 
analysis on the aortic artery (TWAS n=267), coronary 
artery (TWAS n=152), tibial artery (TWAS n=388), and 
whole blood (TWAS n=369), based on the assumption 
that these tissues would be the most relevant for lacunar 
stroke pathogenesis. Bonferroni correction for multiple 
testing was applied, taking into account the total number 
of tested genes across the tissues (cutoff for significance: 
p<1·5 × 10–⁶). TWAS results were further investi gated with 
colocalisation analysis of expression quanti tative trait loci 
and GWAS signals with the R package COLOC,33 to assess 
whether the observed expression quantitative trait loci 
and GWAS associations were consistent with a shared 
association.
In a bioinformatics analysis for novel associations, 
we used Phenoscanner to query whether genome­wide 
signifi cant SNPs were associated with DNA methyla­
tion,34,35 metabolite levels, or protein levels from genome­
wide studies at genome­wide significance (p<5 × 10–⁸) in 
other GWAS. We scanned DrugBank and the Drug Gene 
Interaction Database to assess the therapeutic potential of 
targeting associated genes.36,37
To identify biological pathways significantly associated 
with risk of lacunar stroke, we used the multi­marker 
analysis of genomic annotation (MAGMA) tool.38 We first 
used MAGMA to calculate the significance of each gene 
based on association results, and then used these gene­
level statistics to estimate enrichment of Gene Ontology 
pathways from the Molecular Signatures Database using a 
gene­set enrichment analysis approach.39 We investigated 
only Gene Ontology terms containing at least four and 
fewer than 200 genes and considered pathways attaining a 
false discovery rate (FDR) of less than 0·05 as being 
significantly associated with lacunar stroke.
We did mendelian randomisation analyses to evaluate 
whether any lipid (LDL, HDL, or triglycerides),40 blood 
pressure (systolic blood pressure, diastolic blood pressure, 
pulse pressure),41 metabolic (type 2 diabetes, body­mass 
index),42,43 or lifestyle risk factors (ever smoking) have a 
causal impact on lacunar stroke based on genetics.44,45 
Instrumental variables were independent (LD r²<0·01) 
genome­wide significant (p<5 × 10–⁸) variants associated 
with each trait from previous analyses, and are listed in 
the appendix (pp 9–74). For blood pressure traits, we 
included SNPs associated at genome­wide significance 
with any of the three traits in all analyses. For body­mass 
index, we used the set of independent SNPs provided by 
study authors.42 We calculated the ratio of the SNP risk 
factor effect size by the corresponding effect size for 
lacunar stroke and aggregated effects across all risk factor­
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procedure. As secondary analyses, we used median, 
weighted median, and MR­Egger approaches to aggregate 
across SNPs. We used the MR­Egger intercept to assess 
evidence of directional pleiotropy. In all analyses, we used 
the MendelianRandomization package in R.46 Results are 
presented as odds ratios (ORs) per genetically predicted 
increase in each risk factor (original scale).
Role of the funding source 
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report.
Results 
We meta­analysed studies from Europe, the USA, and 
Australia, including previous GWAS and additional cases 
and controls from the UK DNA Lacunar Stroke studies 
and the International Stroke Genetics Consortium, 
comprising a total of 6030 cases and 248 929 controls of 
European ancestry, and 7338 cases and 254 798 controls in 
the transethnic analysis (figure 1). 2987 (40·7%) cases 
(matched with 29 540 controls) had confirmation by MRI. 
Study cohorts, including genomic inflation λ values, are 
described in the appendix (pp 5–6, 100–11). Following 
meta­analysis, the LD score intercept value in the 
European analysis was 1·046 (SE 0·008) and the λ1000 value 
was 1·007, whereas in the transethnic analysis, the 
λ1000 value was 1·005, indicating no substantial inflation. 
SNP heritability (h²) of MRI­confirmed lacunar stroke, 
calculated using GREML methods in a European ancestry 
subset of 1693 cases and 10 171 controls genotyped on the 
same array, was 0·17–0·21 (SE 0·02), assuming stroke 
prevalence of 1–3%, and that 20% of these are lacunar 
strokes. Using LD score regression, estimates of SNP 
herita bility were lower than GREML estimates, but were 
higher in the MRI­confirmed population (h²=0·065, 
SE 0·017) than in the non­MRI­confirmed population 
(0·0081, 0·0025). The genetic correlation between 
MRI­confirmed and non MRI­confirmed groups using 
LD score regression was significant (rg=0·61, SE 0·21, 
p=0·0033).
Five loci were associated with lacunar stroke: three in 
European samples and three in the transethnic analysis, 
with one locus associated in both (table, figure 2). 
Regional association plots and forest plots for these loci 
are provided in the appendix (pp 115–134). Four of the loci 
were novel and one had been identified previously 
(16q24).6 One other locus (ICA1L-WDR12-CARF-NBEAL1) 
was associated in gene­based analyses in MEGASTROKE, 
and was associated in a recent multi­trait analysis of 
intracerebral haemorrhage and lacunar stroke.5,47
We next applied MTAG to identify additional genetic 
variation underlying lacunar stroke in a joint analysis 
with an aetiologically related trait, cerebral white matter 
hyperintensities (n=42 310). Genetic correlation between 
lacunar stroke and cerebral white matter hyperintensities, 
calculated using LD score regression,22 was substantial for 
the MRI­confirmed group (rg=0·46, SE 0·10, p=4·6 × 10–⁶) 
and slightly lower when including all lacunar strokes 
(0·37, 0·09, p=4·0 × 10–⁵). In the joint analysis with 
cerebral white matter hyperintensities, variants in seven 
additional loci reached genome­wide significance for 
lacunar stroke overall (table, figure 2). Four of these loci 
(SLC25A44-PMF1-BGLAP, LOX-ZNF474-LOC100505841, 
SH3PXD2A, and COL4A2) have previously been associ­
ated with white matter hyperintensities.9,48 Regional 
association plots and forest plots for the loci are provided 
in the appendix (pp 120–134).
None of the 12 loci reaching genome­wide significance 
showed evidence of heterogeneity (p=0·05 to p=0·98; 
appendix pp 123–134). In two regions (SH3PXD2A 
and HTRA1-ARMS2) multiple apparently independent 
(LD r²<0·1) SNPs reached genome­wide significance. 
However, in a joint modelling scenario that was done 
using GCTA­cojo, only a single SNP at each of these 
regions had genome­wide significance, showing that a 
single variant remains the most parsimonious explanation 
of the association at this locus.23 We discarded two regions 
according to our protocol: one region on chromosome 
Figure 2: Manhattan plot of genome-wide SNP associations by genomic position
(A) Lacunar stroke transethnic analysis. (B) Lacunar stroke multi-trait analysis. SNP=single nucleotide 
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For FUSION software see 
https://github.com/gusevlab/
fusion_twas
17q25 showed an association solely with white matter 
hyperintensities, with no association with lacunar stroke 
(lead SNP p=0·39); a second region on chromosome 14 
(EVL-DEGS2), was not as significant in MTAG analysis 
(p=1·2 × 10–⁹) as in white matter hyperintensities alone 
(p=1·2 × 10–¹²), so an independent contribution of lacunar 
stroke to the association could not be determined. Further 
evidence is required to determine whether these two 
regions are associated with lacunar stroke, so they were 
discarded from this analysis. The ZBTB14-EPB41L3 locus 
that was associated with lacunar stroke was not associated 
with white matter hyperintensities (p=0·33 and effect in 
the opposite direction). Similarly, for the ULK4 locus 
associated with lacunar stroke, the lead SNP did not reach 
significance for white matter hyperintensities (p=0·12), 
but it was in the consistent effect direction and thus could 
reflect a lack of study power.
The 12 loci showed stronger effects in the MRI­
confirmed group than in the standard phenotyping group 
(in European ancestry analysis, appendix p 86), although 
the difference was not statistically significant (one­tailed 
p=0·07), with a median proportional increase in OR 
of 3·4%. The 12 loci explained 1·4% of the overall herita­
bility, and 6·5–8·1% of the lacunar stroke heritability 
from GWAS arrays, as calculated in this study.
We did a TWAS to identify genes for which expression 
was associated with lacunar stroke (figure 3). Genetically 
elevated expression of SLC25A44 was associated with 
lacunar stroke in multi­trait analysis in arterial tissues, 
whereas genetically decreased expression of ULK4 was 
associated with lacunar stroke in arterial tissues, whole 
blood, and the brain. At the 2q33·2 locus, genetically 
elevated expression of CARF, FAM117B, ICA1L, and 
NBEAL1 were all associated with lacunar stroke. All associ­
ations were confirmed by colocalisation analysis between 
the gene expression and lacunar stroke associ ations 
(posterior probability >0·7). Five other associations were 
identified in the TWAS, but these were not confirmed by 
colocalisation analysis (posterior probability <0·7, figure 3).
We used Phenoscanner to evaluate whether the 12 lead 
SNPs were associated with DNA methylation, metabolite 
levels, or protein levels from large­scale studies.49–51 11 of 
the 12 lead SNPs showed associations with DNA methyla­
tion at genome­wide significance, which was more than 
expected by chance based on randomly selected SNPs 
across the genome (p<0·01). Ten of the SNPs were associ­
ated in multiple independent studies (appendix pp 87–97). 
Conversely, none of the 12 SNPs were associated with 
metabolite or protein levels.
Querying databases that catalogue drug­gene relation­
ships showed that 11 of the genes listed in table are 
categorised as druggable, indicating that they have poten­
tial for therapeutic development (appendix p 98). However, 
no existing drugs target any of the genes identified in 
this study.
A pathway analysis based on the multi­trait analy­
sis results using MAGMA identified five significantly 
associ ated Gene Ontology gene sets: phosphatidyl­
inositol 5 phosphate binding (p=2·2 × 10–⁶, FDR 0·020), 
extra cellular matrix structural constituent (p=6·2 × 10–⁶, 
0·027), extracellu lar matrix constituent conferring elas­
ticity (p=8·9 × 10–⁶, 0·027), middle ear morphogenesis 
(p=2·3 × 10–⁵, 0·049), and roundabout binding (p=2·7 × 10–⁵, 
0·049). No pathways were significant when based solely on 
lacunar stroke results. Results for all pathways with FDR of 
less than 0·5 are presented in the appendix (pp 75–76).
Figure 3: Genes for which expression is associated with lacunar stroke in six tissues from transcriptome-wide 
association analysis
Evidence of colocalisation of gene expression and lacunar stroke signals is shown by triangle size, with larger 
triangles indicating stronger evidence of colocalisation. CMC=CommonMind Consortium. COLOC.PP4=posterior 
probability of hypothesis 4 in colocalisation analysis (that there is a consistent association between lacunar stroke 
and expression of the given gene). GTEx=Genotype-Tissue Expression portal. WMH=white matter hyperintensities. 
YFS=Young Finns Study.
Lacunar stroke Multi-trait analysis of
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Mendelian randomisation analyses using an inverse 
variance weighted approach found positive associations of 
diastolic, systolic, and pulse pressure, type 2 diabetes, and 
ever smoking with lacunar stroke (figure 4). No significant 
finding showed any evidence of pleiotropy, as assessed 
using the MR­Egger intercept. There was some evidence 
of a negative association between HDL and lacunar 
stroke, but this result did not reach Bonferroni­corrected 
significance. There was no evidence of an association with 
body­mass index, low density lipoprotein or triglycerides. 
Secondary analysis for all risk factors using median, 
weighted median, and MR­Egger approaches are presented 
in the appendix (pp 135–143).
Discussion 
Despite the public health importance of lacunar stroke as 
the cause of a quarter of all strokes, previous GWAS 
studies have only identified one genetic locus associated 
with the disease, in contrast with the 35 identified for 
ischaemic stroke and its major subtypes.5 We did a 
GWAS of lacunar stroke, including the largest number 
of cases with MRI confirmation to date, identifying 
11 novel loci in addition to replicating the one previously 
reported locus.
The primary analysis identified four novel loci. 
One association on chromosome 11, encompassing 
SPI1-SLC39A13-PSMC3-RAPSN, was identified in both 
European and transethnic analyses. The lead SNP is a 
synonymous variant in SLC39A13, which encodes for 
solute carrier family 39 member 13, a transmembrane 
protein with roles in zinc transport. Mutations in this 
gene cause a form of Ehlers­Danlos syndrome, a group of 
connective tissues disorders that affect the vasculature 
and can cause stroke;52 vascular abnormalities have been 
reported in SLC39A13­knockout mice.53 We additionally 
identified a locus for which the lead SNP resides in an 
intron of ULK4 (encoding for serine/threonine­protein 
kinase ULK4) on chromosome 3. The TWAS analysis 
suggests ULK4 is the most likely implicated gene, with 
genetically decreased expression of ULK4 being associated 
with lacunar stroke. Variants in close LD with the lead 
SNP have been implicated in diastolic blood pressure in 
large­scale GWAS.54 However, the direction of effect was 
opposite to that for lacunar stroke, suggesting this likely 
reflects pleiotropy rather than a causal pathway. Variants 
in close LD have also been associated with another 
cardiovascular disease, acute aortic dissection.55 ULK4 
belongs to the family of serine­threonine protein kinases, 
a group of phosphorylating kinases involved in diverse 
processes including cell proliferation and differ entiation, 
apoptosis, and embryonic development. Its deficiency 
leads to hypomyelination,56 and it has been associated 
with neuropsychiatric traits.57 Finally, we report a novel 
association on chromosome 18, located between ZBTB14, 
encoding a zinc finger transcription factor (zinc finger 
and BTB domain­containing protein 14), and EPB41L3, 
encoding for a membrane protein that inhibits cell 
proliferation and promotes apoptosis (erythrocyte mem­
brane protein band 4·1­like 3).
In multi­trait analysis we identified seven further loci, all 
of which are reported as being associated with lacunar 
stroke at genome­wide significance for the first time. 
Two have not been reported as being associated with any 
cerebrovascular disease previously. One locus lies in an 
intergenic region between the VTA1 (vacuolar protein 
sorting­associated protein VTA1 homolog) and GPR126 
(G protein­coupled receptor 126) genes. GPR126 is activated 
by type IV collagen and has an important role in 
myelination.58 GPR126 also binds laminin­211,59 an extra­
cellular matrix protein produced by astrocytes and present 
in the brain, with key roles in development and function 
of the blood­brain barrier,60 in part through regulation of 
pericyte differentiation, a mechanism previously impli­
cated through the FOXF2 gene.61,62 Small vessel disease­
related endothelial dysfunction has also been shown 
to prevent oligodendrocyte precursor cell maturation, 
contributing to impaired myelination.63 One hypothesis 
is that the GPR126 variant might exacerbate this process, 
inhibiting repair from myelin damage. The second 
previously unreported association lies in an intergenic 
region, the nearest gene to which is HTRA1 (encoding for 
serine protease HTRA1), a gene in which rare homozy gous 
variation leads to cerebral autosomal reces sive arterio­
pathy with subcortical infarcts and leucoencephalo pathy.64 
HTRA1, through processing of LTBP­1, promotes TGF­β 
signalling in the vascular extracellular matrix (ECM).65 The 
presence of both rare and common risk variants in HTRA1 
points to it being a key molecule in lacunar stroke 
pathogenesis, and is a feature shared with another gene 
identified in this study, COL4A2, in which rare variants also 
cause monogenic forms of cerebral small vessel disease.7 
Candidate gene studies have previously shown associations 
not reaching genome­wide signi fi cance in COL4A2 with 
lacunar stroke and the same region has also previously 
been associated with intra cerebral haemorrhage in multi­
trait analysis, and coronary artery disease.47,66,67 Four other 
loci identified (SH3PXD2A, LOX-ZNF474-LOC100505841, 
Figure 4: Associations between genetically proxied cardiovascular risk factors and lacunar stroke from 
mendelian randomisation analysis using the inverse variance weighted method
Estimates are presented as ORs per genetically proxied increase in each risk factor (original scale). OR=odds ratio.
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SLC25A44-PMF1-BGLAP, FOXF2-FOXQ1) were associated 
with broad stroke in MEGASTROKE (associations of all 
SNPs in MEGASTROKE are shown in the appendix 
pp 11–18) or a pre vi ous meta­analysis,5,62 although, to 
our knowledge, this is the first study to confirm their 
association specifically with lacunar stroke. At the 
SLC25A44-PMF1-BGLAP locus, the TWAS results point to 
an association of genetically elevated expression of 
SLC25A44 with lacunar stroke, which was validated in 
colocalisa tion analysis. SLC25A44 has an important role 
in catabolism of branched­chain amino acids in brown 
adipose tissue by transporting them into mitochondria,68 
and thus has potential as a mediating factor in the 
relationship between metabolic disease and lacunar stroke. 
However, variants in close LD have also been associated 
with mosaic Y chromosome loss,69 highlighting mosaicism 
as an alternative mechanism. Further functional studies 
will be required to untangle these relationships with 
lacunar stroke. The strength of the association for all 
associated variants was moderate to large in the context of 
GWAS (OR of 1·10 to 1·25 in Europeans) and notably 
larger than effects previously reported for variants associ­
ated with broad stroke phenotypes.5 This observation is 
consistent with the variants acting specifically on the 
lacunar stroke subtype rather than on stroke as a whole.
We also found that 11 of the 12 lead SNPs influence 
DNA methylation at genome­wide significance, pointing 
to epigenetic changes being one source through which 
risk of lacunar stroke is conferred. Whether this genetically 
altered DNA methylation influences transcription of 
nearby genes, and which genes are affected, should be the 
focus of further study. A pathway analysis implicated 
several biological processes in lacunar stroke patho­
physiology. Two pathways involved the ECM, the network 
of extracellular molecules that provide scaffolding and 
biochemical support to surrounding tissues. Disruption 
of the vascular ECM has been hypothesised to be a 
key component in pathogenesis of cerebral small vessel 
disease, particularly in monogenic forms, and several 
of the genes implicated in this study (COL4A2, LOX, 
SH3PXD2A, GPR126, HTRA1) have key roles in the 
ECM.70 Therefore, our findings support this hypothesis 
and suggest ECM dysfunction also has a key role in 
sporadic cerebral small vessel disease.
We did Mendelian randomisation to assess whether 
cardiovascular risk factors showed evidence of a causal 
association with lacunar stroke. We found support for 
genetically predicted elevated blood pressure (systolic, 
diastolic, and pulse pressure), type 2 diabetes, and 
smoking being associated with lacunar stroke. The results 
are consistent with those from observational studies and 
suggest that targeting these factors would reduce risk 
of lacunar stroke.71 There was evidence, not reaching 
Bonferroni­corrected significance, for a protective effect 
of increased HDL on risk of lacunar stroke, and no 
association with LDL, replicating findings in previous 
studies.72,73 Overall these findings show that the impact of 
the direct effects of LDL­lowering medications, such as 
statins, on the incidence of lacunar stroke is likely to 
be small.
Our study emphasises the benefit of accurate pheno­
typing using MRI. Using this approach, the heritability of 
lacunar stroke using GREML was substantial, and larger 
than previous estimates based on TOAST subtyping.74 
Using LD score, the heritability was larger in the MRI­
confirmed group, but estimates were considerably lower 
than for GREML. The use of MRI subtyping also increased 
the strength of association for the lacunar stroke­associated 
variants, although this increase was not statistically 
significant. These results suggest that further genetic risk 
factor studies in lacunar stroke are likely to be more 
successful if MRI subtyping is used.
Our study has limitations. The analysis was done in a 
predominantly European ancestry population. Large 
studies including diverse ancestries should be done to 
assess the generalisability of our findings to all ethnic 
groups. The MTAG approach relies on the relatively 
strong assumption that associated variants act on both 
traits, which might not always be the case for white matter 
hyperintensities and lacunar stroke, because they reflect 
downstream effects of a shared common ancestor, small 
vessel disease. To control for this, we considered only 
SNPs showing an association with both traits and showing 
greater significance in MTAG analysis than with white 
matter hyperintensities or lacunar stroke alone, as being 
significant. However, independent replication will remain 
the gold standard for confirming these and all other 
reported associations in this Article. Previous studies have 
suggested that a more conservative threshold of a p value 
less than 1 × 10–⁸ should be considered in GWAS using 
larger imputation panels such as this study.75 If we were to 
use this threshold, one locus (ZBTB14-EPB41L3) would no 
longer be significant. Additional caution should therefore 
be applied when interpreting this finding, particularly as it 
was not significant in MTAG analysis. To increase sample 
size and study power, we used publicly available controls 
in analyses. As such, we could not determine whether 
these individuals had a history of lacunar stroke. Our 
analyses did not adjust for age and sex, and there is an 
ongoing debate about the importance of including such 
covariates in genetic studies.76 In analyses with substantial 
differences between case and control populations, subtle 
biases could occur.
In summary, these findings represent substantial 
progress in identifying the genetic mechanisms under­
lying lacunar stroke, a disease for which little is known 
about the molecular causes. Our findings highlight 
diverse mechanisms contributing to the disease, implicat­
ing disruption of the vascular ECM (COL4A2, LOX, 
SH3PXD2A, GPR126, HTRA1), pericyte differenti ation 
(FOXF2, GPR126), TGF­β signalling (HTRA1), and 
myelina tion (ULK4, GPR126) in disease risk. These results 
provide novel insights into the pathogenesis of lacunar 
stroke, and highlight multiple candidates for functional 
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experiments to identify the specific mechanisms con­
ferring risk of lacunar stroke that could be targeted 
therapeutically.
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